Science Stories
As we deepen our commitment to oncology, we’re focused on bringing forward meaningful innovation for patients, especially those facing rare and aggressive cancers like H3 K27M-mutant diffuse midline glioma. With the FDA approval of the first treatment for this cancer, there is new hope for patients and families who are navigating this life-threatening disease.
Narcolepsy is an often misunderstood and under-recognized condition. Cataplexy is a major symptom of narcolepsy, a chronic neurological condition that involves other symptoms such as excessive daytime sleepiness – that can result in difficulty focusing and maintaining alertness, along with sleep paralysis and vivid hallucinations when falling asleep or waking up.
We’re committed to developing life-changing medicines that can redefine the possibilities for life after a cancer diagnosis — in particular for patients with certain types of secondary acute myeloid leukemia (AML).
In the treatment of cancer, one size does not fit all. At Actelion, our researchers are committed to discovering new possibilities for delivering innovative treatments as effectively and safely as possible.